Understanding the Market | SINOMAB BIO-B rose over 7% in the afternoon as the bridging study for the subcutaneous injection formulation of SM17 in China completed dosing of the first cohort of healthy subjects
SINOMAB BIO-B's stock price rose over 7% in the afternoon, with an increase of 6.33% as of the time of publication, trading at HKD 1.68, with a transaction volume of HKD 11.7838 million. The company announced that the bridging study for the subcutaneous injection formulation of SM17 has successfully completed the administration to the first cohort of healthy subjects, with all subjects tolerating well and no adverse events reported. The study aims to investigate the safety, tolerability, and pharmacokinetic characteristics of SM17, with recruitment expected to be completed by November 2025 and follow-up completed by March 2026. SM17 is the world's first humanized IgG4-κ monoclonal antibody, with the potential to treat skin inflammation
According to Zhitong Finance APP, SINOMAB BIO-B (03681) rose over 7% in the afternoon, and as of the time of publication, it was up 6.33%, trading at HKD 1.68, with a transaction volume of HKD 11.7838 million.
In terms of news, SINOMAB BIO announced that the bridging study for the SM17 subcutaneous injection conducted in China was successfully completed for the first cohort of healthy subjects on October 14. As of the date of this announcement, all subjects have tolerated the treatment well, with no adverse events reported. This bridging study aims to investigate the safety, tolerability, and pharmacokinetic characteristics of the SM17 subcutaneous injection and to explore the bioavailability of SM17 in humans. A total of 30 healthy subjects are planned to be enrolled in this bridging study. All healthy subjects are expected to complete recruitment by November 2025 and complete all follow-ups by March 2026.
SM17 is a novel, globally pioneering humanized IgG4-κ monoclonal antibody that can regulate the type II allergic response pathway by targeting the key molecule interleukin 25 (IL-25) receptor in the targeted vigilance pathway. The company believes that upstream therapies targeting the Th2 inflammatory cytokine pathway will have a broad impact on skin inflammation, indicating that SM17 has significant potential for safer and more effective treatment of atopic dermatitis (AD) with differentiated advantages
